Literature DB >> 15680160

Selecting for antibody scFv fragments with improved stability using phage display with denaturation under reducing conditions.

Eeva-Christine Brockmann1, Matthew Cooper, Nelli Strömsten, Markus Vehniäinen, Petri Saviranta.   

Abstract

Stability of single-chain Fvs (scFvs) can be improved by mutagenesis followed by phage display selection where the unstable variants are first inactivated by, for example, denaturing treatment. Here we describe a modified strategy for the selection of stabilized antibody fragments by phage display, based on denaturation under reducing conditions. This strategy was applied to an anti-thyroid-stimulating hormone (TSH) scFv fragment which refolded remarkably during the selection if denaturation was carried out in conventionally used non-reducing conditions. Refolding was, however, efficiently prevented by combining denaturation with reduction of the intra-domain disulfide bridges, which created favourable conditions for selection of clones with improved stability. Using this strategy, scFv mutants with 8-9 degrees C improved thermal stability and 0.8-0.9 M improved stability for guanidinium chloride were found after 4-5 enrichment cycles. The most stable mutants selected contained either Lys(H)66Arg or Asn(H)52aSer mutations, which are known to stabilize other scFvs. Periplasmic expression level of the mutants was also improved.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15680160     DOI: 10.1016/j.jim.2004.11.008

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  16 in total

1.  Arginine mutations in antibody complementarity-determining regions display context-dependent affinity/specificity trade-offs.

Authors:  Kathryn E Tiller; Lijuan Li; Sandeep Kumar; Mark C Julian; Shekhar Garde; Peter M Tessier
Journal:  J Biol Chem       Date:  2017-08-04       Impact factor: 5.157

Review 2.  Molecular engineering of antibodies for therapeutic and diagnostic purposes.

Authors:  Frédéric Ducancel; Bruno H Muller
Journal:  MAbs       Date:  2012-07-01       Impact factor: 5.857

3.  Co-evolution of affinity and stability of grafted amyloid-motif domain antibodies.

Authors:  Mark C Julian; Christine C Lee; Kathryn E Tiller; Lilia A Rabia; Evan K Day; Arthur J Schick; Peter M Tessier
Journal:  Protein Eng Des Sel       Date:  2015-09-19       Impact factor: 1.650

Review 4.  The use of single chain Fv as targeting agents for immunoliposomes: an update on immunoliposomal drugs for cancer treatment.

Authors:  W W Cheng; T M Allen
Journal:  Expert Opin Drug Deliv       Date:  2010-04       Impact factor: 6.648

Review 5.  Drugs derived from phage display: from candidate identification to clinical practice.

Authors:  Andrew E Nixon; Daniel J Sexton; Robert C Ladner
Journal:  MAbs       Date:  2014 Jan-Feb       Impact factor: 5.857

Review 6.  Stability of protein pharmaceuticals: an update.

Authors:  Mark Cornell Manning; Danny K Chou; Brian M Murphy; Robert W Payne; Derrick S Katayama
Journal:  Pharm Res       Date:  2010-02-09       Impact factor: 4.200

7.  Anti-FLT3 nanoparticles for acute myeloid leukemia: Preclinical pharmacology and pharmacokinetics.

Authors:  Mincheol Park; Vijaya Pooja Vaikari; Albert T Lam; Yong Zhang; John Andrew MacKay; Houda Alachkar
Journal:  J Control Release       Date:  2020-05-16       Impact factor: 9.776

8.  Anti-Abeta single-chain antibody delivery via adeno-associated virus for treatment of Alzheimer's disease.

Authors:  Ken-ichiro Fukuchi; Kazuki Tahara; Hong-Duck Kim; J Adam Maxwell; Terry L Lewis; Mary Ann Accavitti-Loper; Helen Kim; Selvarangan Ponnazhagan; Robert Lalonde
Journal:  Neurobiol Dis       Date:  2006-09       Impact factor: 5.996

9.  Evaluation of antidiphtheria toxin nanobodies.

Authors:  Ghada H Shaker
Journal:  Nanotechnol Sci Appl       Date:  2010-06-17

10.  Anti-tumor activity of stability-engineered IgG-like bispecific antibodies targeting TRAIL-R2 and LTbetaR.

Authors:  Jennifer S Michaelson; Stephen J Demarest; Brian Miller; Aldo Amatucci; William B Snyder; Xiufeng Wu; Flora Huang; Samantha Phan; Sharon Gao; Adam Doern; Graham K Farrington; Alexey Lugovskoy; Ingrid Joseph; Veronique Bailly; Xin Wang; Ellen Garber; Jeff Browning; Scott M Glaser
Journal:  MAbs       Date:  2009-03-11       Impact factor: 5.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.